BARNADAS MOLINS, AGUSTI FGS
abarnadasm@santpau.cat
Aguado Sorolla, Maria FGS
Alfonso Ruiz, Rosa IR
Andres Granyo, Marta FGS
Andres Nieto, Marta IR
Anguera Palacios, Georgia FGS
Arqueros Nuñez, Cristina FGS
Barba Joaquin, Andres FGS
Bosma Ainaud, Freya FGS
Bustamante Pardo, Diego A. IR
Calvo Verges, Nuria FGS
Carmona Alonso, Ana IR
Castells Tello, Diana IR
Cerda Serda, Paula FGS
Clua Serra, Marina IR
Colomer Merino, Lucia IR
Cotaina Recio, Maria FGS
Escuin Borras, Daniel IR
Flores Pino, Juan Francisco FGS
Gallego Rubio, Oscar Salvador FGS
Garcia Belinchon, Maria De La Merce IR
Gisbert Beamud, Alexandra IR
Gonzalez Guerrero, Laura IR
Hernandez Garcia, Ricardo IR
Juan Linares, Eva FGS
Lavernia Rosell, Laia IR
Layana Antepara, Michelle Elizabeth IR
Llobet Busquets, Mireia IR
Lopez Sanmartin, Consuelo FGS
Majem Tarruella, Margarita FGS
Maroto Rey, Jose Pablo FGS
Martin Cullell, Berta FGS
Martinez Aranda, Rodrigo A. IR
Martinez Recio, Sergio FGS
Menendez Cuervo, Dulce Maria IR
Molina Bayona, Silvia IR
Molina Perez, Maria Alejandra FGS
Mora Brugues, Josefina FGS
Moreno Gomez, Laura IR
Nieva Muñoz, Maria FGS
Paez Lopez-bravo, David FGS
Perez Gorrini, Tiziana Giselle IR
Portu Grive, Mikel FGS
Ramirez De Olano, Amaya FGS
Ramirez Garcia, Ona IR
Reyes Vilasalo, Judith IR
Ribas Bellavista, Laia IR
Ribas Carbonell, Romina IR
Rivera Vargas, Pablo Irene FGS
Roca Sola, Marc IR
Romano Cardozo, Alejandra FGS
Romero Montenegro, Daniel FGS
Salazar Blanco, Juliana IR
Sanchez Del Rio, Sofia FGS
Sanchez Villanueva, Kenia IR
Sanz Beltran, Judit FGS
Sebio Garcia, Ana FGS
Serra Lopez, Jorgina FGS
Suris Cumicheo, Paola M. IR
Teres Lleida, Raul FGS
Tibau I Martorell, Ariadna FGS
Vall Montero, Gaudi IR
Van Veen Romero, Erika IR
Virgili Manrique, Anna Cristina FGS
(JIF 2024)
-Abu A, Krayim B, Amir E, Tibau A, Robson ME, Abuhadra N, Chen Y, Shepshelovich D, Goldvaser H. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2024; 202:104455. DOI:10.1016/j.critrevonc.2024.104455. PMID:39067779. IF:5,600 (Q1/2D). Document type: Review.
-Agarwal N, Castellano D, Alonso T, Arija J, Colomba E, Gravis G, Mourey L, Oudard S, Fléchon A, González M, Rey PM, Schweizer MT, Gallardo E, Johnston E, Balar A, Haddad N, Appiah AK, Nacerddine K, Piulats JM. A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1. CLINICAL CANCER RESEARCH. 2024; 30(11). DOI:10.1158/1078-0432.CCR-23-3436. PMID:38512117. IF:10,200 (Q1/1D). Document type: Article.
-Alserawan L, Mulet M, Anguera G, Riudavets M, Zamora C, Osuna R, Serra J, Joaquín AB, Sullivan I, Majem M, Vidal S. Kinetics of IFN?-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors. Cancers. 2024; 16(9):1759. DOI:10.3390/cancers16091759. PMID:38730712. IF:4,400 (Q2/3D). Document type: Article.
-Anguera G, Mulet M, Zamora C, Osuna R, Barba A, Sullivan I, Serra J, Cantó E, Vidal S, Majem M. Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients. Biomedicines. 2024; 12(5):958. DOI:10.3390/biomedicines12050958. PMID:38790920. IF:3,900 (Q1/3D). Document type: Article.
-Aranha MR, Montal V, van den Brink H, Pegueroles J, Carmona M, Videla L, Blesa LM, Benejam B, Arranz J, Valldeneu S, Barroeta I, Fernández S, Ribas L, Alcolea D, González S, Bargalló N, Biessels GJ, Blesa R, Lleó A, Coutinho AM, Leite CC, Bejanin A, Fortea J. Cortical microinfarcts in adults with Down syndrome assessed with 3T-MRI. Alzheimers & Dementia. 2024; 20(6). DOI:10.1002/alz.13797. PMID:38644660. IF:11,100 (Q1/1D). Document type: Article.
-Arqueros C, Gallardo A, Vidal S, Osuna R, Tibau A, Bell OL, Cajal T, Lerma E, Lobato B, Salazar J, Barnadas A. Clinical Relevance of Tumour-Infiltrating Immune Cells in HER2-Negative Breast Cancer Treated with Neoadjuvant Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(5):2627. DOI:10.3390/ijms25052627. PMID:38473874. IF:4,900 (Q1/3D). Document type: Article.
-Barba A, López L, Ferre M, Majem M, Martinez S, Bell O, Arranz MJ, Salazar J, Sullivan I. ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer. Pharmaceutics. 2024; 16(9):1121. DOI:10.3390/pharmaceutics16091121. PMID:39339159. IF:5,500 (Q1/1D). Document type: Article.
-Bellmunt J, Maroto P, Bonfill T, Vazquez F, Perez JL, Juanpere N, Hernandez A, Hernandez S, Rovira A, Juan OS, Rodriguez A. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. Clinical Genitourinary Cancer. 2024; 22(5):102123. DOI:10.1016/j.clgc.2024.102123. PMID:38905731. IF:2,700 (Q2/3D). Document type: Article.
-Borque A, Zapatero A, Manneh R, Alonso T, Couñago F, Domínguez M, López M, Rodríguez A, Sala N, Sanmamed N, Maroto P, Guard Invest Multidisciplinar Tumores Genitourinarios GRP. Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection. Actas Urologicas Espanolas. 2024; 48(9). DOI:10.1016/j.acuro.2024.03.002. PMID:38740263. IF:1,200 (Q3/7D). Document type: Article.
-Caballero M, Piedra A, Gallego O, López A, Castillo P, Navarrete P, Prat A, Grau JJ. Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Brazilian Journal of Otorhinolaryngology. 2024; 90(6):101493. DOI:10.1016/j.bjorl.2024.101493. PMID:39205362. IF:1,800 (Q2/4D). Document type: Article.
-Casanovas A, Estanyol B, Ciendones M, Padròs J, Cuartero J, Barnadas A, García B, González R, Sebio R, Masià J. Effectiveness of an Exercise and Educational-Based Prehabilitation Program in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy (PREOptimize) on Functional Outcomes: A Randomized Controlled Trial. PHYSICAL THERAPY. 2024; 104(12):pzae151. DOI:10.1093/ptj/pzae151. PMID:39423256. IF:3,300 (Q1/1D). Document type: Article.
-Conde E, Hernandez S, Carrillo JLR, Martinez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez L, Majem M, Paz L, Lopez F. RET Fusion Testing in Patients With NSCLC: The RETING Study. Jto Clinical And Research Reports. 2024; 5(4):100653. DOI:10.1016/j.jtocrr.2024.100653. PMID:38525319. IF:3,500 (Q1/3D). Document type: Article.
-Contreras D, Jiménez P, López CL, Montes AF, Muñoz A, Rivera FV, Alonso V, Alcaide J, Salvà F, Rúa MC, Guillot M, Carnicero AM, Mate RJ, García SC, Martínez EA, Astorga BG, Fernandez AB, Villaroel PG, Manrique A, Sosa MM, Alonso B, Castiñeiras AC, López CC, Aparicio J, Carmona A. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?. BRITISH JOURNAL OF CANCER. 2024; 130(5). DOI:10.1038/s41416-023-02563-w. PMID:38191609. IF:6,800 (Q1/2D). Document type: Article.
-Day E, Gavira J, Tapia JC, Anguera G, Maroto P. What About Variant Histologies in Bladder Cancer?. European Urology Focus. 2024; 10(2). DOI:10.1016/j.euf.2024.05.015. PMID:38849276. IF:5,600 (Q1/1D). Document type: Review.
-Di AM, Schenker M, Medioni J, Mandziuk S, Majem M, Gravis G, Cornfeld M, Ranganathan S, Lou S, Csoszi T. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). ESMO Open. 2024; 9(3):102387. DOI:10.1016/j.esmoop.2024.102387. PMID:38401247. IF:8,300 (Q1/2D). Document type: Article.
-Escuin D, Bell O, García B, Clos M, Larrañaga I, López L, Mora J, Andrés M, Arqueros C, Barnadas A. Small Non-Coding RNAs and Their Role in Locoregional Metastasis and Outcomes in Early-Stage Breast Cancer Patients. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2024; 25(7):3982. DOI:10.3390/ijms25073982. PMID:38612790. IF:4,900 (Q1/3D). Document type: Article.
-Fernandez A, Elez E, de la Haba J, Paez D, Mendez MJ, Felip E, Rodriguez A. Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology. Clinical & Translational Oncology. 2024; 26DOI:10.1007/s12094-023-03225-2. PMID:37316754. IF:2,500 (Q3/6D). Document type: Article.
-Fernández CM, Sebio A, Rincón JO, Broto JM, Benlloch AM, Plaza DM, Pousa AL, Alegría IG, Giuppi M, Ballesteros EC, Bernabeu D, de Alava E, Morales CV. Clinical practice guidelines for the treatment of Ewing sarcoma (Spanish Sarcoma Research Group-GEIS). Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03602-5. PMID:39158802. IF:2,500 (Q3/6D). Document type: Review.
-García P, Elez E, Soto J, Páez D, Fernández A, Graña B, Salud A, Yubero A, Gómez MA, Macías I, Quintero G, López C, Fernández T, Grávalos C, González E, Guix M, Paredes BG, Reina JJ, Mowbray JRR, Sastre J, Aranda E, Treatment Digestive Tumors TTD. Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial. ESMO Open. 2024; 9(12):103986. DOI:10.1016/j.esmoop.2024.103986. PMID:39608305. IF:8,300 (Q1/2D). Document type: Article.
-García P, Jimenez P, Soto J, Baraibar I, Santos C, La Casta A, Ghanem I, Cortijo G, Méndez A, Pazo R, Vera R, Melián M, Alcaide J, Graña B, Páez D, Gallego I, Lobo M, Borregón M, Montes A, de Castro E, Carmona A, Aranda E, Spanish Cooperat Treatment Digest Tumors GRPTTD. Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study. ONCOLOGIST. 2024; DOI:10.1093/oncolo/oyae300. PMID:39550209. IF:4,200 (Q2/3D). Document type: Article.
-Gately L, Mesía C, Sepúlveda JM, del Barco S, Pineda E, Gironés R, Fuster J, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). JOURNAL OF NEURO-ONCOLOGY. 2024; 168(2). DOI:10.1007/s11060-024-04668-5. PMID:38630385. IF:3,100 (Q2/4D). Document type: Article.
-Gavira J, Tapia JC, Romano A, Anguera G, Aguado M, Piedra A, Bosma F, Sánchez S, Martin C, Algaba F, Arce Y, Cajal TRY, Maroto P. Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution. Clinical & Translational Oncology. 2024; 26(10). DOI:10.1007/s12094-024-03483-8. PMID:38722534. IF:2,500 (Q3/6D). Document type: Article.
-Gray JE, Markovets A, Reungwetwattana T, Majem M, Nogami N, Peled N, Lee JS, Cho BC, Chewaskulyong B, John T, Han JY, Sebastian M, Todd A, Rukazenkov Y, Barrett C, Chmielecki J, Lee SM, Ramalingam SS, Hartmaier R. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of Thoracic Oncology. 2024; 19(11). DOI:10.1016/j.jtho.2024.07.008. PMID:39029876. IF:20,800 (Q1/1D). Document type: Article.
-Gronchi A, Palmerini E, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Brunello A, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Pizzamiglio S, Verderio P, Fontana V, Donati DM, Palassini E, Sanfilippo R, Bianchi G, Bertuzzi A, Morosi C, Pasquali S, Stacchiotti S, Bagué S, Coindre JM, Miceli R, Dei AP, Casali PG. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(8). DOI:10.1200/JCO.23.00908. PMID:38232337. IF:41,900 (Q1/1D). Document type: Article.
-Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez MJ, Hong SH, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Onkourologiya. 2024; 20(1). DOI:10.17650/1726-9776-2024-20-1-24-35. IF:0,100 (Q4/10D). Document type: Article.
-Krebs MG, Forster M, Majem M, Peguero J, Iams W, Clay T, Roxburgh P, Doger B, Bajaj P, Barba A, Perera S, Mueller C, Triebel F. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. Jto Clinical And Research Reports. 2024; 5(11):100725. DOI:10.1016/j.jtocrr.2024.100725. PMID:39403626. IF:3,500 (Q1/3D). Document type: Article.
-Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L, Karlan BY, Aeilts A, Eng C, Bordeleau L, Foulkes WD, Tung N, Couch FJ, Fruscio R, Cajal T, Singer CF, Neuhausen SL, Zakalik D, Cybulski C, Gronwald J, Huzarski T, Stempa K, Dungan J, Cullinane C, Olopade OI, Metcalfe K, Sun P, Narod SA, Hereditary Breast Canc C. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 2024; DOI:10.1001/jamaoncol.2023.6944. PMID:38421676. IF:20,100 (Q1/1D). Document type: Article.
-Mármol MCC, Aguado M, Cajal TRY, Gallardo A, Catasus L, Gonzalez A, Mendez JE, Lasa A, Arumi M, Rubio OG, Serra JB, Hernandez FM, von A, Kommoss FKF, Espinosa I. Non-C19MC-altered embryonal tumor with multilayered rosettes in a young woman with DICER1 syndrome: case report and review of the literature. Pathologica. 2024; 116(3). DOI:10.32074/1591-951X-970. PMID:38979591. IF:2,900 (Q2/4D). Document type: Review.
-Martín B, Virgili AC, Riera P, Fumagalli C, Mirallas O, Pelegrín FJ, Sánchez S, Molina V, Szafranska J, Páez D. Histopathological, Clinical, And Molecular (HICAM) score for patients with colorectal liver metastases. BRITISH JOURNAL OF SURGERY. 2024; 111(3):znae016. DOI:10.1093/bjs/znae016. PMID:38488528. IF:8,800 (Q1/1D). Document type: Article.
-Mateo FJP, Guasch AD, Pineda J, Manrique A, Cullell BM, López DP, Díaz JG, Cascón AP, Freiria XB. Capecitabine-Related Thrombotic Microangiopathy. Journal Of Gastrointestinal Cancer. 2024; 55(2). DOI:10.1007/s12029-023-00993-6. PMID:38175385. IF:1,600 (Q4/9D). Document type: Article.
-Mirallas O, Martin B, Navarro V, Vega KS, Recuero J, Gómez D, López D, de Torres CS, Andurell L, Pedrola A, Berché R, Palmas F, Ucha JM, Villacampa G, Rezqallah A, Sanz J, Bach R, Bueno S, Viaplana C, Molina G, Hernando A, Aguilar J, Roca M, Muñoz E, Martínez A, Alonso A, Eremiev S, Macarulla T, Oaknin A, Saura C, Élez E, Felip E, Peñuelas A, Burgos R, Pardo PG, Garralda E, Tabernero J, Serradell S, Servitja S, Paez D, Dienstmann R, Carles J. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study. Lancet Regional Health-Europe. 2024; 46:101063. DOI:10.1016/j.lanepe.2024.101063. PMID:39529819. IF:13,000 (Q1/1D). Document type: Article.
-Morcillo AO, Zsadanyi SE, Arriola JE, Carmona M, Montal V, Pegueroles J, Aranha MR, Vaque L, Padilla C, Benejam B, Videla L, Barroeta I, Fernandez S, Altuna M, Gimenez S, Gonzalez S, Bargallo N, Ribas L, Arranz J, Torres S, Iulita MF, Belbin O, Camacho V, Alcolea D, Lleo A, Fortea J, Bejanin A. Characterization of white matter hyperintensities in Down syndrome. Alzheimers & Dementia. 2024; 20(9). DOI:10.1002/alz.14146. PMID:39087352. IF:11,100 (Q1/1D). Document type: Article.
-Moreno JM, Feliubadaló L, Pineda M, Prada P, Ramos M, Del Valle J, Brunet J, Gel B, Currás M, Calsina B, Salazar ME, Rodríguez M, Roig B, Fernández S, Domínguez M, Ledo M, Sanz MI, Castillejo A, Dámaso E, Soto JL, de Miguel M, Calero B, Sánchez JM, Ramon T, Lasa A, Gisbert A, López A, Ruiz C, Potrony M, Alvarez M, Osorio A, Lorda I, Robledo M, Cascon A, Ruiz A, Spataro N, Hernan I, Borràs E, Moles A, Earl J, Cadiñanos J, Sánchez AB, Bigas A, Capellá G, Lazaro C, SpadaHC C. SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population. Database-The Journal of Biological Databases and Curation. 2024; 2024:baae055. DOI:10.1093/database/baae055. PMID:38965703. IF:3,600 (Q1/2D). Document type: Article.
-Motzer RJ, Porta C, Eto M, Powles T, Gruenwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani A, De Giorgi U, Melichar B, Hong SH, Gurney H, Mendez MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong SR, Bedke J, Schmidinger M, Rodriguez K, Burgents J, He CX, Okpara CE, Mckenzie J, Choueiri TK, CLEAR I. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(11). DOI:10.1200/JCO.23.01569. PMID:38227898. IF:41,900 (Q1/1D). Document type: Article.
-Ospina AV, Nadal SB, de la Cruz JLCC, Larriba JLG, Vidueira IM, Sureda BM, Nadal E, Trancho FH, Kindelan AA, Morillo E, Caro RB, Barrera JB, de Juan VC, Rubio JC, de Castro J, Ramos AC, Dols MC, Gomez M, Almanzar S, Campelo RG, Molla AI, Sarceda JRJ, Maestre UJ, Castro RL, Majem M, Martinez A, Tellez EM, Lorente DS, Provencio M. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03382-y. PMID:38530556. IF:2,500 (Q3/6D). Document type: Review.
-Palmerini E, Pousa AL, Grignani G, Redondo A, Hindi N, Provenzano S, Sebio A, Martin J, Valverde C, Trufero JM, Gutierrez A, de Alava E, Gomez M, D’Ambrosio L, Collini P, Bazzocchi A, Moura DS, Ibrahim T, Stacchiotti S, Broto JM. Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial. CANCER. 2024; 131(1). DOI:10.1002/cncr.35628. PMID:39540661. IF:5,100 (Q1/3D). Document type: Article.
-Peressini M, Garcia R, Massuti B, Marti C, Cobo M, Gutiérrez V, Dómine M, Fuentes J, Majem M, de Castro J, Córdoba JF, Diz MP, Isla D, Esteban E, Carcereny E, Vila L, Moreno A, Ros S, Moreno A, García FJ, Huidobro G, Aguado C, Cebey V, Valdivia J, Palmero R, Lianes P, López M, Vidal OJ, Provencio M, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V, Ponce S, Nuñez A, Ucero A, Hernandez S, Lopez F, Conde E, Paz L, Zugazagoitia J. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 2024; 30(14). DOI:10.1158/1078-0432.CCR-24-0104. PMID:38630755. IF:10,200 (Q1/1D). Document type: Article.
-Piedra A, Martínez S, Hernández A, Morán T, Arriola E, Recuero J, Cobo M, Cordeiro P, Mosquera J, Fernández M, García R, Calles A, Alvarez R, Zapata M, Isla D, Callejo A, Iranzo P, Serra J, Barba A, Sullivan I, Felip E, Majem M. First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study. Frontiers in Oncology. 2024; 14:1510278. DOI:10.3389/fonc.2024.1510278. PMID:39741981. IF:3,300 (Q2/4D). Document type: Article.
-Provencio M, de Lope LR, Serna R, Nadal E, Tain PD, Massuti B, González JL, Insa A, Sánchez A, Casal J, Garcia R, López SS, Rogado J, Martínez A, Bosch J, Bernabé R, Estévez SV, Ponce S, de Castro J, Sarto JC, Reguart N, Dómine M, Aguilar A, Majem M, Estival A, Cabia SP, Martín AL, González M, Cobo M, Camps C, Barneto I, Calvo V, Collazo A, Cruz A, Romero A. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC. LUNG CANCER. 2024; 194:107865. DOI:10.1016/j.lungcan.2024.107865. PMID:38945004. IF:4,400 (Q1/2D). Document type: Article.
-Provencio M, Nadal E, Insa A, Campelo RG, Casal J, Dómine M, Massuti B, Majem M, Rodríguez D, Martínez A, de Castro J, de Antonio DG, Macia I, Figueroa S, Vago LF, Calvo V, Palmero R, Sierra B, Martínez C, Molina M, Serna R, Romero A, Cruz A. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. LANCET ONCOLOGY. 2024; 25(11). DOI:10.1016/S1470-2045(24)00498-4. PMID:39419061. IF:35,900 (Q1/1D). Document type: Article.
-Puente J, Pinto A, Mendez MJ, del Muro XG, Maroto P, Vazquez S, Luque R, Anido U, Strunz T, Upadhyay A, Montes J, Nuñez AO, Portela JG, Castellano D. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03734-8. PMID:39365365. IF:2,500 (Q3/6D). Document type: Article.
-Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, López R, Bosch J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Nana FA, Ponce S, Albarrán V, Dal A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier JB, Audigier C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Mezquita L, Planchard D. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2024; 25(3). DOI:10.1016/j.cllc.2023.11.007. PMID:38105153. IF:3,300 (Q2/4D). Document type: Article.
-Rodriguez A, Valderrama BP, Castellano D, Pinto A, Mellado B, Puente J, Climent MA, Domenech M, Vazquez F, Perez JL, Bonfill T, Morales R, Gonzalez E, Garcia X, Maroto P, Navarro N, Juanpere N, Juan O, Bellmunt J. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024; 9(9):103690. DOI:10.1016/j.esmoop.2024.103690. PMID:39214051. IF:8,300 (Q1/2D). Document type: Article.
-Rofes P, Dueñas N, del Valle J, Navarro M, Balmaña J, Ramón y Cajal T, Tuset N, Castillo C, González S, Brunet J, Capellá G, Lázaro C, Pineda M. Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation. Cancer Medicine. 2024; 13(7):e7041. DOI:10.1002/cam4.7041. PMID:38558366. IF:3,100 (Q2/5D). Document type: Article.
-Rueda AG, Taus A, Alvarez RA, Bernabé R, Chara L, López M, Vilà L, González M, Aldagalán A, Herrera BE, Castro RL, Cabellos RA, Doménech M, Falagan S, Vega AM, Aguado C, Barba A, Ureña MTD, Isla D, Hernández LB, Pérez JLF, Juan O, Massuti B, Mielgo X, Ortega AL, Catot S, Dómine M, Escoín C, Navalón FG, Gil I, Muñoz S, Rodríguez D, Roldán RMV, Curbera GA, León L, Padilla A, Lario AP, Sánchez JM, Garrido P, Spanish Lung Canc GRP. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical & Translational Oncology. 2024; 26(9). DOI:10.1007/s12094-024-03404-9. PMID:38512450. IF:2,500 (Q3/6D). Document type: Article.
-Salazar J, Arranz MJ, Martin J, Bautista F, Martínez J, Martínez J, Vidal Y, Echebarria A, Díaz R, Valverde C, Luna P, Vaz MA, Blay P, Alvarez R, Sebio A. Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol. Pharmaceutics. 2024; 16(12):1585. DOI:10.3390/pharmaceutics16121585. PMID:39771563. IF:5,500 (Q1/1D). Document type: Article.
-Salazar J, Garcia E, Fernández A, Esteve M, Gisbert JP, Busquets D, Lucendo A, Márquez L, Guardiola J, Martín MD, Iglesias E, Monfort D, Villoria A, Cañete F, Bell O, Ricart E, Zabana Y, Chaparro M, Domènech E, Gordillo J, ENEIDA G. Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024; 90(5). DOI:10.1111/bcp.16017. PMID:38369687. IF:3,000 (Q2/4D). Document type: Article.
-Salazar J, Riera P, Gordillo J, Altès A, Martínez M, Serès M, Llaó J, Giordano A, Garcia E. Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn’s disease patients. PHARMACOGENOMICS JOURNAL. 2024; 24(4):20. DOI:10.1038/s41397-024-00341-2. PMID:38906864. IF:2,900 (Q2/4D). Document type: Article.
-Santero M, Meade AG, Selva A, Savall O, Bracchiglione J, Macías I, Leache L, Cerdà P, Cosp XB, Appropriateness Systemic Oncological Treatment Adv Canc ASTAC R. Utilising systematic reviews to assess potential overtreatment and claim for better evidence-based research: an analysis of anticancer drugs versus supportive care in advanced esophageal cancer. Systematic Reviews. 2024; 13(1):186. DOI:10.1186/s13643-024-02594-1. PMID:39026378. IF:3,900 (Q1/2D). Document type: Article.
-Schreurs M, Cajal TRY, Adank MA, Collee JM, Hollestelle A, van J, Schmidt MK, Hooning MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. BREAST. 2024; 73:103611. DOI:10.1016/j.breast.2023.103611. PMID:38039887. IF:7,900 (Q1/1D). Document type: Article.
-Shachar SS, Korzets Y, Shepshelovich D, Zlothover N, Amir E, Tibau A, Goldvaser H. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review. CANCER TREATMENT REVIEWS. 2024; 122:102666. DOI:10.1016/j.ctrv.2023.102666. PMID:38064877. IF:10,500 (Q1/1D). Document type: Review.
-Tapia JC, Bosma F, Gavira J, Sanchez S, Molina MA, Sanz J, Martin C, Anguera G, Maroto P. Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021. Clinical Genitourinary Cancer. 2024; 22(3):102047. DOI:10.1016/j.clgc.2024.01.019. PMID:38430859. IF:2,700 (Q2/3D). Document type: Article.
-Tapia JC, Gavira J, Anguera G, Sanchez S, Romano A, Bosma F, Molina A, Sanz J, Martin C, Algaba F, Maroto P. Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis. Clinical & Translational Oncology. 2024; 26(7). DOI:10.1007/s12094-024-03393-9. PMID:38421563. IF:2,500 (Q3/6D). Document type: Article.
-Tibau A, Hwang TJ, Avorn J, Kesselheim AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ-British Medical Journal. 2024; 386:e079126. DOI:10.1136/bmj-2023-079126. PMID:39164034. IF:42,700 (Q1/1D). Document type: Article.
-Tibau A, Hwang TJ, Molto C, Avorn J, Kesselheim AS. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies. JAMA Oncology. 2024; 10(5). DOI:10.1001/jamaoncol.2024.0194. PMID:38573645. IF:20,100 (Q1/1D). Document type: Article.
-Torres S, Llop A, Gutiérrez S, Romey M, Teulé A, Llort G, Herrero A, Sánchez P, Vallmajó A, González S, Chirivella I, Cano JM, Graña B, Simonetti S, de Corcuera ID, Cajal TRY, Sanz J, Serrano S, Otero A, Churruca C, Sánchez AB, Servitja S, Guillén C, Brunet J, Denkert C, Serra V, Balmaña J. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Network Open. 2024; 7(4):e247811. DOI:10.1001/jamanetworkopen.2024.7811. PMID:38648056. IF:9,700 (Q1/1D). Document type: Article.
-Vidal N, Climent MA, Pérez S, Méndez MJ, Anguera G, Salas IM, Gallardo E, Cuéllar MA, Molina J, Martín A, Rodriguez A, Casado EA, Gonzalez M, Domènech M, Kareaga MM, Calvo OF, Guzmán JCV, Estévez SV, Gonzàlez A, Puente J. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03744-6. PMID:39369361. IF:2,500 (Q3/6D). Document type: Article.
-Viñolas N, Mezquita L, Corral J, Cobo M, Gil F, Paz L, Remon J, Rodríguez M, Ruano A, Conde E, Majem M, Garrido P, Felip E, Isla D, de Castro J. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium. Clinical & Translational Oncology. 2024; 26(2). DOI:10.1007/s12094-023-03262-x. PMID:37490262. IF:2,500 (Q3/6D). Document type: Article.
-Virgili AC, Salazar J, Gallardo A, López A, Terés R, Bagué S, Orellana R, Fumagalli C, Mangues R, Alba L, Unzueta U, Casanova I, Sebio A. CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas. Diagnostics. 2024; 14(11):1195. DOI:10.3390/diagnostics14111195. PMID:38893721. IF:3,300 (Q1/2D). Document type: Article.
-Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, Heuvel MHV, Linardou H, Cho BC, Roberts R, Tanaka K, Blais N, Schvartsman G, Hansen KH, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. LUNG CANCER. 2024; 196:107921. DOI:10.1016/j.lungcan.2024.107921. PMID:39303400. IF:4,400 (Q1/2D). Document type: Article.
(JIF 2023)
-Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Alvarez JB, Hummel HD, Dingemans A, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang TY, Martinez P, Anderson ES, Paz L, DeLLphi I. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; DOI:10.1056/NEJMoa2307980. PMID:37861218. IF:96,200 (Q1/1D). Document type: Article.
-Annesi I, Cecchi L, Biagioni B, Chung KF, Clot B, Coen MC, Amato GD, Damialis A, Dominguez J, Galan C, Gilles S, Holgate S, Jeebhay M, Kazadzis S, Papadopoulos NG, Quirce S, Sastre J, Tummon F, Traidl C, Walusiak J, Alonso P, Canelo C, Cantero Y, Rigau D, Salazar J, Verdugo F, Jutel M, Akdis CA, Agache I. Is exposure to pollen a risk factor for moderate and severe asthma exacerbations?. ALLERGY. 2023; 78(8). DOI:10.1111/all.15724. PMID:36961370. IF:12,600 (Q1/1D). Document type: Review.
-Arqueros C, Salazar J, Gallardo A, Andrés M, Tibau A, Bell OL, Artigas A, Lasa A, Cajal T, Lerma E, Barnadas A. Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients. Biomedicines. 2023; 11(12):3231. DOI:10.3390/biomedicines11123231. PMID:38137452. IF:3,900 (Q1/3D). Document type: Article.
-Bertran J, Giménez A, Román R, Talbot S, Whiteley R, Floc’h N, Martínez E, Martin MJ, Smith PD, Sullivan I, Terp MG, Saeh J, Marino C, Fabbri G, Guo G, Xu M, Tornador C, Aguilar A, Reguart N, Ditzel HJ, Martínez A, Nabau N, Gascó A, Rosell R, Pease JE, Polanska UM, Travers J, Urosevic J, Molina MA. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors. Molecular Cancer. 2023; 22(1):110. DOI:10.1186/s12943-023-01815-w. PMID:37443114. IF:27,700 (Q1/1D). Document type: Article.
-Blakely CM, Weder W, Bubendorf L, He J, Majem M, Shyr Y, Chaft JE. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. LUNG CANCER. 2023; 177. DOI:10.1016/j.lungcan.2023.01.002. PMID:36736076. IF:4,500 (Q1/2D). Document type: Review.
-Blanco R, Dómine M, González JL, Loutfi S, Alfaro J, Saldaña J, Rubio J, Campos B, Hidalgo J, Barba A, Márquez D, Martin M, Olaverri A, Nadal E. Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. LUNG CANCER. 2023; 183:107318. DOI:10.1016/j.lungcan.2023.107318. PMID:37557022. IF:4,500 (Q1/2D). Document type: Article.
-Bracchiglione J, Rodríguez G, Requeijo C, Santero M, Salazar J, Salas K, Meade A-G, Antequera A, Auladell A, Quintana MJ, Solà I, Urrútia G, Acosta R, Bonfill X. Systemic Oncological Treatments versus Supportive Care for Patients with Advanced Hepatobiliary Cancers: An Overview of Systematic Reviews. Cancers. 2023; 15(3):766. DOI:10.3390/cancers15030766. PMID:36765723. IF:4,500 (Q1/3D). Document type: Review.
-Campos F, Téres R, Sebio A, Bettim BB, Martinez J. Survival Differences of Patients with Resected Extraskeletal Osteosarcoma Receiving Two Different (Neo)Adjuvant Chemotherapy Regimens: A Systematic Review and Meta-analysis. CLINICAL ONCOLOGY. 2023; 35(12). DOI:10.1016/j.clon.2023.09.009. PMID:37777356. IF:3,200 (Q2/5D). Document type: Article.
-Canto E, Anguera G, Jimenez N, Mellado B, Ramirez O, Mariscal A, Maroto P, Vidal S. Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment. Diagnostics. 2023; 13(13):2222. DOI:10.3390/diagnostics13132222. PMID:37443615. IF:3,000 (Q1/2D). Document type: Article.
-Carmona E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Epidermolysis bullosa acquisita induced by atezolizumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; DOI:10.1111/ddg.15203. PMID:37658659. IF:5,500 (Q1/1D). Document type: Letter.
-Casanovas A, Sebio R, Ciendones M, Cuartero J, Estanyol B, Padrós J, García B, Barnadas A, Masia J. Prehabilitation in Patients With Breast Cancer Receiving Neoadjuvant Therapy to Minimize Musculoskeletal Postoperative Complications and Enhance Recovery (PREOPtimize): A Protocol for a Randomized Controlled Trial. PHYSICAL THERAPY. 2023; 103(9):pzad062. DOI:10.1093/ptj/pzad062. PMID:37318267. IF:3,500 (Q1/1D). Document type: Article.
-Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hartmaier RJ, Ramalingam SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 2023; 14(1):1070. DOI:10.1038/s41467-023-35961-y. PMID:36849494. IF:14,700 (Q1/1D). Document type: Article.
-De Castro J, Insa A, Collado R, Escudero V, Martínez A, Fernandez E, Sullivan I, Arrabal N, Carcedo D, Manzaneque A. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulmonary Medicine. 2023; 23(1):69. DOI:10.1186/s12890-023-02356-0. PMID:36809990. IF:2,600 (Q2/5D). Document type: Article.
-de Velasco G, Alonso T, Rodríguez A, Anguera G, Campayo M, Pinto Á, Ortega EM, Gallardo E, Núñez NF, García I, Reig O, Méndez MJ, Fernández O, Cassinello NV, Torregrosa D, López A, Rosero A, Valiente PG, de España CG, Climent MA, Santasusana MD, Sánchez ÁR, González IC, Afonso R, García del Muro X, Casinello J, Fernández EM, García L, Afonso J, Polo SH, Asensio Ú. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. Clinical Genitourinary Cancer. 2023; 21(3):e166-e174. DOI:10.1016/j.clgc.2022.11.021. PMID:36610891. IF:2,300 (Q2/5D). Document type: Article.
-Escuin D, López L, Bell O, Mora J, García B, Moral A, Clos M, Boronat L, Arqueros C, Barnadas A. Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(17):13293. DOI:10.3390/ijms241713293. PMID:37686099. IF:4,900 (Q1/3D). Document type: Article.
-Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios GA, Dionese M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Quiroga MNG, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Molina J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Cattrini C, Nogueira L, de Carvalho R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchenhorn D, Santini D, Manneh R, Bisonni R, Zakopoulou R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Sorgentoni G, Battelli N, Porta C, Bellmunt J, Santoni M. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; 72(11). DOI:10.1007/s00262-023-03518-z. PMID:37676282. IF:4,600 (Q1/3D). Document type: Article.
-Frezza AM, Stacchiotti S, Chibon F, Coindre JM, Italiano A, Romagnosa C, Bagué S, Dei AP, Braglia L, Palmerini E, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Brunello A, Blay JY, Beveridge RD, Lugowska I, Lesluyes T, Maestro R, Merlo FD, Casali PG, Gronchi A. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study. Cancer Medicine. 2023; 12(2). DOI:10.1002/cam4.5015. PMID:35848358. IF:2,900 (Q2/5D). Document type: Article.
-Fumagalli C, Orellana R, Ferre M, Gonzalez A, Catasus L, Vazquez T, Sebio A, Lopez A, Llauger J, Peiro A, Antonescu CR. Expanding the molecular landscape of undifferentiated sarcomas of bone with a novel EWSR1-SSX3 gene fusion. GENES CHROMOSOMES & CANCER. 2023; 63(1). DOI:10.1002/gcc.23215. PMID:38050902. IF:3,100 (Q2/4D). Document type: Article.
-Garcia JA, Blancas I, Echavarria I, Hinojo C, Margeli M, Moreno F, Pernas S, Cajal TRY, Ribelles N, Bellet M. SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03203-8. PMID:37148499. IF:2,800 (Q2/5D). Document type: Article.
-Garcia R, González B, Vidal R, Contreras D, Pericay C, Fernández A, Falcó E, González M, Reina JJ, Alonso V, Rodríguez N, Gil M, Santos C, Páez D, Anton B, Aguilar F, Morales P. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Clinical & Translational Oncology. 2023; DOI:10.1007/s12094-023-03309-z. PMID:37651021. IF:2,800 (Q2/5D). Document type: Article.
-Garcia R, Sullivan I, Arriola E, Insa A, Vidal O, Cruz P, Moran T, Reguart N, Zugazagoitia J, Domine M. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03216-3. PMID:37418123. IF:2,800 (Q2/5D). Document type: Article.
-Giménez A, Sánchez E, de Lope LR, Aguilar A, Sullivan I, Calvo V, Moya I, Viteri S, Cabrera C, Aguado C, Armiger N, Valarezo J, Mayo C, Reguart N, Rosell R, Provencio M, Romero A, Molina MA. Detecting ALK, ROS1, and RET fusions and the MET?ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. Molecular Oncology. 2023; 17(9). DOI:10.1002/1878-0261.13468. PMID:37243883. IF:5,000 (Q1/3D). Document type: Article.
-González S, Molina V, Homs R, Martín B, Rodríguez M, González JA, López A, Moral A, Sánchez S. Surgical and oncological results after surgical treatment of patients diagnosed with sarcoma liver metastases. CIRUGIA ESPANOLA. 2023; 101(2). DOI:10.1016/j.ciresp.2021.11.005. PMID:35901963. IF:1,300 (Q3/7D). Document type: Article.
-Gray JE, Ahn MJ, Oxnard GR, Shepherd FA, Imamura F, Cheng Y, Okamoto I, Cho BC, Lin MC, Wu YL, Majem M, Gautschi O, Boyer M, Bulusu KC, Markovets A, Barrett JC, Hodge R, McKeown A, Hartmaier RJ, Chmielecki J, Papadimitrakopoulou VA, Ramalingam SS. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. CLINICAL CANCER RESEARCH. 2023; 29(17). DOI:10.1158/1078-0432.CCR-22-3146. PMID:37379430. IF:10,400 (Q1/1D). Document type: Article.
-Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez MJ, Hong S-H, Winquist E, Goh JC, Maroto P, Buchler T, Takagi T, Burgents JE, Perini R, He C, Okpara CE, McKenzie J, Choueiri TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Frontiers in Oncology. 2023; 13:1223282. DOI:10.3389/fonc.2023.1223282. PMID:37664025. IF:3,500 (Q2/4D). Document type: Article.
-Grunwald V, Powles T, Kopyltsov E, Kozlov V, Alonso T, Eto M, Hutson T, Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong SR, Melichar B, Rolland F, Oya M, Rodriguez K, Saito K, McKenzie J, Porta C. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. European Urology Oncology. 2023; 6(4). DOI:10.1016/j.euo.2023.01.010. PMID:36720658. IF:8,300 (Q1/1D). Document type: Article.
-Herbst RS, Wu Y-L, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim S-W, Yu C-J, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, De Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(10). DOI:10.1200/JCO.22.02186. PMID:36720083. IF:42,100 (Q1/1D). Document type: Article.
-Isla D, Felip E, Garrido P, Insa A, Majem M, Remon J, Trigo JM, de Castro J. A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. Clinical & Translational Oncology. 2023; 25(1). DOI:10.1007/s12094-022-02941-5. PMID:36168085. IF:2,800 (Q2/5D). Document type: Article.
-Isla D, Sanchez A, Casal J, Cobo M, Majem M, Reguart N, Zugazagoitia J, Bernabe R. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement. Journal of Clinical Medicine. 2023; 12(15):5063. DOI:10.3390/jcm12155063. PMID:37568465. IF:3,000 (Q1/2D). Document type: Article.
-Jimenez P, Foy V, Raby S, Carmona A, Macía L, Arrazubi V, Cacho D, Hernandez San Gil R, Custodio A, Cano JM, Fernández A, Mirallas O, Macias I, Vidal R, Visa L, Limón ML, Pimentel P, Martínez N, Sauri T, Martín M, Mangas M, Gil M, Calvo A, Reguera P, Granja M, Martín A, Hernández C, Cerdá P, Gomez L, Garcia F, Pacheco V, Gutierrez D, Ruiz M, Weaver J, Mansoor W, Gallego J. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology. 2023; 15:17588359231157641. DOI:10.1177/17588359231157641. PMID:36895850. IF:4,300 (Q2/3D). Document type: Article.
-John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su W-C, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu Y-L, Tsuboi M, Herbst RS, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. Journal of Thoracic Oncology. 2023; 18(9). DOI:10.1016/j.jtho.2023.05.015. PMID:37236398. IF:21,000 (Q1/1D). Document type: Article.
-John T, Majem M, Legg D, Goldman J. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. Targeted Oncology. 2023; 18(1). DOI:10.1007/s11523-022-00927-5. PMID:36534268. IF:4,400 (Q2/3D). Document type: Editorial Material.
-Kobel M, Kang EY, Weir A, Rambau PF, Lee CH, Nelson GS, Ghatage P, Meagher NS, Riggan MJ, Alsop J, Anglesio MS, Beckmann MW, Bisinotto C, Boisen M, Boros J, Brand AH, Brooks A, Carney ME, Coulson P, Courtney M, Cushing KL, Cybulski C, Deen S, El MA, Elishaev E, Erber R, Fereday S, Fischer A, Gayther SA, Barquin A, Gentry A, Gilks CB, Gronwald H, Grube M, Harnett PR, Harris HR, Hartkopf AD, Hartmann A, Hein A, Hendley J, Hernandez BY, Huang YJ, Jakubowska A, Jimenez M, Jones ME, Kennedy CJ, Kluz T, Koziak JM, Lesnock J, Lester J, Lubinski J, Longacre TA, Lycke M, Mateoiu C, McCauley BM, McGuire V, Ney B, Olawaiye A, Orsulic S, Osorio A, Paz L, Cajal TRY, Rothstein JH, Ruebner M, Schoemaker MJ, Shah MT, Sharma R, Sherman ME, Shvetsov YB, Singh N, Steed H, Storr SJ, Talhouk A, Traficante N, Wang C, Whittemore AS, Widschwendter M, -Wilkens LR, Winham SJ, Benitez J, Berchuck A, Bowtell DD, dos FJC, Campbell I, Cook LS, DeFazio A, Doherty JA, Fasching PA, Fortner RT, Garcia MJ, Goodman MT, Goode EL, Gronwald J, Huntsman DG, Karlan BY, Kelemen LE, Kommoss S, Le ND, Martin SG, Menon U, Modugno F, Pharoah PDP, Schildkraut JM, Sieh W, Staebler A, Sundfeldt K, Swerdlow AJ, Ramus SJ, Brenton JD, AOCS GRP. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology Clinical Research. 2023; 9(3). DOI:10.1002/cjp2.311. PMID:36948887. IF:3,400 (Q1/3D). Document type: Article.
-López A, González P, Sanz J, Prieto JD, Trias I, Luque RJ, Semidey ME, Maroto P, Algaba F. Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP. Revista Espanola De Patologia. 2023; 56(4). DOI:10.1016/j.patol.2023.05.001. PMID:37879823. Document type: Review.
-Lozano R, Castro E, FL, Thorne H, Ramirez M, Aragon IM, Cendon Y, Gutierrez A, Salles DC, Romero N, Lorente D, Gonzalez P, Calatrava A, Alonso C, Anido U, Arevalo S, Balmana J, Chirivella I, Juan MJ, Llort G, Cajal TRY, Almagro E, Alameda D, Lopez PP, Herrera B, Mateo J, Pritchard CC, Antonarakis ES, Lotan TL, Rubio J, Sandhu S, Olmos D. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. EUROPEAN JOURNAL OF CANCER. 2023; 185. DOI:10.1016/j.ejca.2023.02.022. PMID:36972661. IF:7,600 (Q1/2D). Document type: Article.
-Macaulay VM, Lord S, Hussain S, Maroto JP, Jones RH, Climent MÁ, Cook N, Lin CC, Wang SS, Bianchini D, Bailey M, Schlieker L, Bogenrieder T, de Bono J. A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. BRITISH JOURNAL OF CANCER. 2023; 129(6). DOI:10.1038/s41416-023-02380-1. PMID:37537253. IF:6,400 (Q1/2D). Document type: Article.
-Manzano JL, Martin J, Fernández LA, Benítez G, Medina J, Quindós M, García A, Fernández O, Simo RV, Majem M, Bellido L, Ayala de Miguel P, Campos B, Espinosa E, Macías JA, Gil I, Lorente D, Rodriguez A, Perez VN, López R, Gramaje MG, Puértolas T, Rodriguez JF, Espasa L, Belaustegui G, Cerezuela P. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study. MELANOMA RESEARCH. 2023; 33(5). DOI:10.1097/CMR.0000000000000888. PMID:36988401. IF:1,500 (Q3/7D). Document type: Article.
-Martin J, Martinez J, Moura DS, Redondo A, Gutierrez A, Lopez A, Martinez J, Sevilla I, Diaz R, Solis MP, Carnero A, Perez M, Marcilla D, Garcia J, Romero P, Fernandez J, Lopez D, Arribas I, Hindi N. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A. Signal Transduction and Targeted Therapy. 2023; 8(1):405. DOI:10.1038/s41392-023-01661-8. IF:40,800 (Q1/1D). Document type: Article.
-Martinez DAS, Quilez A, Jimenez P, Sesma A, Tarazona N, Pacheco V, Obispo B, Paez D, Quintanar T, Sanchez M, Montes AF, Felip E, Rodriguez A, Elez E. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section. Clinical & Translational Oncology. 2023; 25(3). DOI:10.1007/s12094-022-02989-3. PMID:36418642. IF:2,800 (Q2/5D). Document type: Article.
-Martinez N, Vilarino N, Alameda F, Mojal S, Arumi M, Carrato C, Aldecoa I, Ribalta T, Vidal N, Bellosillo B, Menendez S, Del Barco S, Gallego O, Pineda E, Lopez R, Hernandez A, Mesia C, Esteve A, de la Iglesia N, Balana C, Martinez M, Navarro P. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. Cells. 2023; 12(6):843. DOI:10.3390/cells12060843. PMID:36980184. IF:5,100 (Q2/4D). Document type: Article.
-Mayayo C, de Heredia ML, Prat E, Gonzalez L, Guarch ME, Vilches C, Munoz L, Asensi MA, Serra C, Llebaria A, Casado M, Artuch R, Garrabou G, Garcia PM, Pallardo FV, Nunes V. The antioxidant L-Ergothioneine prevents cystine lithiasis in the Slc7a9-/- mouse model of cystinuria. Redox Biology. 2023; 64:102801. DOI:10.1016/j.redox.2023.102801. PMID:37418888. IF:10,700 (Q1/1D). Document type: Article.
-Nadal E, Oré M, Remon J, Bernabé R, Covela M, de Castro J, Massutí B, Guillot M, Majem M, Maestu I, Morilla I, Gironés R. Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer. Clinical & Translational Oncology. 2023; 25(11). DOI:10.1007/s12094-023-03286-3. PMID:37566345. IF:2,800 (Q2/5D). Document type: Article.
-Nadal E, Rodríguez D, Simó M, Massutí B, Juan O, Huidobro G, López R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilariño N, Navarro V, Bruna J. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(28). DOI:10.1200/JCO.22.02561. PMID:37603816. IF:42,100 (Q1/1D). Document type: Article.
-O’Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto JP, Ferrario C, Carret A-S, Yu Y, Guseva M, Homet B, Rosenberg JE. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(25). DOI:10.1200/JCO.22.02887. PMID:37369081. IF:42,100 (Q1/1D). Document type: Article.
-Peters S, Letovanec I, Mauer M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N, Tarruella MM, Casas J, Tsourti Z, Marti N, Kammler R, Danson S, O’Brien M, Stahel RA. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. LUNG CANCER. 2023; 175. DOI:10.1016/j.lungcan.2022.12.004. PMID:36535121. IF:4,500 (Q1/2D). Document type: Article.
-Pilcher L, Pahlke S, Urquhart O, O’Brien KK, Dhar V, Fontana M, Gonzalez C, Keels MA, Mascarenhas AK, Nascimento MM, Platt JA, Sabino GJ, Slayton RL, Tinanoff N, Young DA, Zero DT, Tampi MP, Purnell D, Salazar J, Megremis S, Bienek D, Carrasco A. Direct materials for restoring caries lesions Systematic review and meta-analysis-a report of the American Dental Association Council on Scientific Affairs. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION. 2023; 154(2). DOI:10.1016/j.adaj.2022.09.012. PMID:36610925. IF:3,100 (Q1/2D). Document type: Article.
-Provencio M, Estival A, Franco F, López G, Saigí M, Arasanz H, Diz P, Carcereny E, García J, Aguado C, Mosquera J, Iruarrizaga E, Majem M, Bosch J, Mielgo X, Guirado M, Juan Ó, Blasco A, Lucía C, Del Barrio A, De Portugal T, López A, Serrano G, Campos B, Rubio J, Catot S, Esteban B, Martí JL, del Barco E, Calvo V. Immunogenicity of COVID-19 vaccines in lung cancer patients. LUNG CANCER. 2023; 184:107323. DOI:10.1016/j.lungcan.2023.107323. PMID:37639820. IF:4,500 (Q1/2D). Document type: Article.
-Provencio M, Ortega AL, Coves J, Calvo V, Marsé R, Dómine M, Guirado M, Carcereny E, Fernández N, Álvarez R, Blanco R, León L, Sánchez JM, Sullivan IG, Cobo M, Sánchez A, Massuti B, Sierra B, Mártinez C, Serna R, Romero A, Cruz A. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncology. 2023; 9(3). DOI:10.1001/jamaoncol.2022.5959. PMID:36520426. IF:22,500 (Q1/1D). Document type: Article.
-Remon J, Besse B, Aix SP, Callejo A, Al K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazieres J, Curcio H, Wasag B, Pretzenbacher Y, Fournier B, Dingemans A, Dziadziuszko R. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. ANNALS OF ONCOLOGY. 2023; 34(5). DOI:10.1016/j.annonc.2023.02.012. PMID:36863484. IF:56,700 (Q1/1D). Document type: Article.
-Rodriguez A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez M, Juanpere N, Juan O, Bellmunt J. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. BRITISH JOURNAL OF CANCER. 2023; 128(1). DOI:10.1038/s41416-022-01991-4. PMID:36289372. IF:6,400 (Q1/2D). Document type: Article.
-Roldan JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez A, Monteagudo M, Mellid S, Leandro LJ, Montero C, Cascon A, Roncador G, Coloma J, Robledo M, Rodriguez C. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. INTERNATIONAL JOURNAL OF CANCER. 2023; 153(6). DOI:10.1002/ijc.34575. PMID:37260183. IF:5,700 (Q1/2D). Document type: Article.
-Rueda A, Mendoza JI, Alba L, Parladé E, Voltà E, Paez D, Aviño A, Eritja R, Vázquez E, Villaverde A, Mangues R, Unzueta U. Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs). Science China-Materials. 2023; 66(10). DOI:10.1007/s40843-023-2571-6. IF:6,800 (Q1/3D). Document type: Article.
-Salazar J, Bracchiglione J, Savall O, Antequera A, Bottaro D, Gutierrez M, Martinez S, Pericay C, Tibau A, Bonfill X, Appropriateness SYSTT. Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review. BMC CANCER. 2023; 23(1):748. DOI:10.1186/s12885-023-11207-4. PMID:37573294. IF:3,400 (Q2/4D). Document type: Review.
-Sanchez A, Cajal TRY, Pineda M, Aguirre E, Grana B, Chirivella I, Balmana J, Brunet J, SEOM Hereditary Canc Working GRP, AEGH Hereditary Canc C. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03202-9. PMID:37133731. IF:2,800 (Q2/5D). Document type: Article.
-Sanfilippo R, Hindi N, Jurado JC, Blay JY, Lopez A, Italiano A, Alvarez R, Gutierrez A, Rincon I, Sangalli C, Aguiar JLP, Romero J, Morosi C, Sunyach MP, Fabbroni C, Romagosa C, Ranchere D, Dei AP, Casali PG, Martin J, Gronchi A. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma A Nonrandomized Clinical Trial. JAMA Oncology. 2023; 9(5). DOI:10.1001/jamaoncol.2023.0056. PMID:36995731. IF:22,500 (Q1/1D). Document type: Article.
-Segura PP, Quintela NV, Garcia MM, Berron SD, Sarrio RG, Gomez JG, Castano AG, Martin LMN, Rubio OG, Losada EP. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03245-y. PMID:37540408. IF:2,800 (Q2/5D). Document type: Article.
-Serrano C, Álvarez R, Carrasco JA, Marquina G, Martínez J, Martínez V, Sala MÁ, Sebio A, Sevilla I, Martín J. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clinical & Translational Oncology. 2023; 25(9). DOI:10.1007/s12094-023-03177-7. PMID:37129716. IF:2,800 (Q2/5D). Document type: Article.
-Tibau A, Martínez MT, Ramos M, De La Cruz L, Santaballa A, O’Connor M, Martínez N, Moreno F, Fernández I, Virizuela JA, Alarcón J, de La Haba J, Sánchez P, Albacar CR, Bueno C, Kelly C, Casas M, Bezares S, Rosell L, Albanell J. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic Advances in Medical Oncology. 2023; 15:17588359221148921. DOI:10.1177/17588359221148921. PMID:36743520. IF:4,300 (Q2/3D). Document type: Article.
-Trilla L, Gámez A, Prado G, López R, Soriano V, Garicano F, Lecumberri MJ, Rodríguez de la Borbolla M, Majem M, Pérez E, González M, Oramas J, Magdaleno A, Fra J, Martín A, Corral M, Puértolas T, Ramos R, Dittmann A, Nanni P, Fresno JÁ, Espinosa E. Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma. Cancers. 2023; 15(17):4407. DOI:10.3390/cancers15174407. PMID:37686682. IF:4,500 (Q1/3D). Document type: Article.
-Trilla L, Gámez A, Prado G, López R, Zapater A, López E, Lumbreras MI, Soriano V, Garicano F, Lecumberri MJ, de la Borbolla MR, Majem M, Pérez E, González M, Oramas J, Magdaleno A, Fra J, Martín A, Corral M, Puértolas T, Ramos R, Vara J, Espinosa E. Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(1):801. DOI:10.3390/ijms24010801. PMID:36614248. IF:4,900 (Q1/3D). Document type: Article.
-Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, De Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL, ADAURA I. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(2). DOI:10.1056/NEJMoa2304594. PMID:37272535. IF:96,200 (Q1/1D). Document type: Article.
-Tsutani Y, Goldman JW, Dacic S, Yatabe Y, Majem M, Huang X, Chen A, van der Gronde T, He J. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023; 24(4). DOI:10.1016/j.cllc.2023.02.002. PMID:36872181. IF:3,300 (Q2/4D). Document type: Article.
-Valcarcel S, Gallego J, Jimenez P, Diez M, de Castro EM, Hernandez R, Arrazubi V, Custodio A, Cano JM, Montes AF, Macias I, Visa L, Calvo A, Tocino RV, Lago NM, Limon ML, Granja M, Gil M, Pimentel P, Macia L, Perez CH, Mangas M, Carnicero AM, Cerda P, Gonzalez LG, Navalon FG, Rambla MDM, Richard MM, Carmona A. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; 149(7). DOI:10.1007/s00432-022-04294-6. PMID:36042046. IF:2,700 (Q3/6D). Document type: Article.
-Vazquez JC, Antolin S, Ruiz M, Servitja S, Alba E, Barnadas A, Lluch A, Martin M, Rodriguez A, Sola I, Bonfill X, Urrutia G, Sanchez P. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis. Clinical & Translational Oncology. 2023; 25(4). DOI:10.1007/s12094-022-02998-2. PMID:36417083. IF:2,800 (Q2/5D). Document type: Review.
-Vazquez JC, Pinero A, de Castro FJ, Lluch A, Martin M, Barnadas A, Alba E, Rodriguez A, Rojo F, Gimenez J, Sola I, Quintana MJ, Bonfill X, Urrutia G, Sanchez P. The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review. Clinical & Translational Oncology. 2023; 25(2). DOI:10.1007/s12094-022-02953-1. PMID:36153763. IF:2,800 (Q2/5D). Document type: Review.
-Vidal J, Fernández MC, Casadevall D, García P, Páez D, Guix M, Alonso V, Cano MT, Santos C, Durán G, Elez E, Manzano JL, Garcia R, Ferreiro R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. CLINICAL CANCER RESEARCH. 2023; 29(2). DOI:10.1158/1078-0432.CCR-22-1696. PMID:36074154. IF:10,400 (Q1/1D). Document type: Article.
-Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, Chen K-N, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(6). DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:96,200 (Q1/1D). Document type: Article.
(JIF 2022)